Article thumbnail

The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines

By Stacey L Fossey, Misty D Bear, Jiayuh Lin, Chenglong Li, Eric B Schwartz, Pui-Kai Li, James R Fuchs, Joelle Fenger, William C Kisseberth and Cheryl A London
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3074561
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). [An investigation on formation mechanisms and preparation of curcumin phospholipid complex]. Zhongguo Zhong Yao Za Zhi
  2. (2010). Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis.
  3. (2010). Agarwal MG: Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem
  4. (2010). Aggarwal BB: Bisdemethylcurcumin and structurally related hispolon analogues of curcumin exhibit enhanced prooxidant, anti-proliferative and antiinflammatory activities in vitro. Biochem Pharmacol
  5. (2006). Aggarwal BB: Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).
  6. (2007). AJ: Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol
  7. (2010). al: A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer
  8. (2008). Alarcon de la Lastra C: New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res
  9. (2003). Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res
  10. (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist
  11. (2009). Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.
  12. (2009). Chung JG: Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett
  13. cleavage by caspases: impact on full-length Stat3 expression, fragment formation, and transcriptional activity.
  14. (1998). CM: Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis
  15. (2003). CM: STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling.
  16. (1991). Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res
  17. (2009). Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. Anticancer Drugs
  18. (2010). Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest
  19. (2006). Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells. Biochem Pharmacol
  20. (2006). CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol
  21. (2003). de Lorimier LP: Update on the biology and management of canine osteosarcoma. Vet Clin North Am Small Anim Pract
  22. (2010). Differential Inhibition of Protein Translation Machinery by Curcumin in Normal, Immortalized, and Malignant Oral Epithelial Cells. Cancer Prev Res (Phila Pa)
  23. (2010). du Bois A: Poly (ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Expert Rev Anticancer Ther
  24. (2009). Ee PL: Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs
  25. (1999). et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity
  26. (2005). et al: Construction of a 2-Mb Fossey et al.
  27. (2010). et al: Curcumin blocks migration and invasion of mouse-rat hybrid retina ganglion cells (N18) through the inhibition of MMP-2, -9, FAK, Rho A and Rock-1 gene expression. Oncol Rep
  28. (2009). et al: New curcumin analogues exhibit enhanced growthsuppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci
  29. (2010). et al: Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res
  30. (2007). et al: Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells.
  31. (2010). et al: The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer
  32. (2009). Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem
  33. Fan QY: Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma.
  34. (2008). Fuchs B: Cytotoxic effects of curcumin on osteosarcoma cell lines. Invest New Drugs
  35. (2010). GJ: The aberrant expressions of nuclear matrix proteins during the apoptosis of human osteosarcoma cells. Anat Rec (Hoboken)
  36. (1998). Hirano T: Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive elementbinding protein.
  37. (2006). Huang S: Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res
  38. (2003). I: Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domaincontaining tyrosine phosphatase 2 in brain microglia.
  39. (2010). IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle
  40. (2008). JA: [Changes of nuclear matrix proteins during apoptosis of human osteosarcoma MG-63 cells induced by curcumin]. Fen Zi Xi Bao Sheng Wu Xue Bao
  41. (2009). JH: Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells. Anticancer Res
  42. (2009). London CA: Characterization of STAT3 activation and expression in canine and human osteosarcoma.
  43. (2011). LS: Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase C inhibito. Leuk Lymphoma
  44. (2010). Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett
  45. (2009). Majumdar AP: Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr Cancer
  46. (2006). Naturally occurring translational models for development of cancer gene therapy. Gene Ther Mol Biol
  47. (2009). New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells.
  48. (2010). Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
  49. (2007). PK: Curcuminphospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats.
  50. (2009). PK: Structure-activity relationship studies of curcumin analogues. Bioorg Med Chem Lett
  51. (2008). QP: Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res
  52. (2001). Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
  53. (2000). STAT proteins: novel molecular targets for cancer drug discovery. Oncogene
  54. (2009). TH: Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients.
  55. (2003). Thamm DH, Radinsky R: c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis
  56. (2010). TM: Priming of Signal Transducer and Activator of Transcription Proteins for CytokineTriggered Polyubiquitylation and Degradation by the A2a Adenosine Receptor. Mol Pharmacol
  57. (2010). TT: Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies.
  58. (2002). Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol
  59. (2011). Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.
  60. (2000). Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res
  61. (2009). Yadav S: Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease.